
Access Patient Per Provider Clinical Indications - Airway Clearance Therapy (ACT) • Respiratory Tract Infections Hypersecretions/ Ineffective Cough Immobility or muscle weakness **Evaluate Patient's Clinical Indications** Difficulty w/ secretion clearance • Sputum Production > 5cc w/ cough or suctioning • Hx of Chronic Bronchitis, Pneumonia Bronchiectasis, **Aspiration** • Cough Peak Flow < 270 LPM Clinical Indications – Volume **Expansion Therapy (VET)** • IS Inspiratory Capacity < 10 ml/kg Disorders of the Diaphragm Predisposing conditions w/ risk of pulmonary atelectasis, thoracic surgery, upper abdominal surgery Suboptimal Oxygen levels Presence of neuromuscular disease · Restrictive Lung Defect

Mobility/Ambulatory Impairment

Volume Expansion/Pulmonary Hygiene Flowchart & Therapy Modality Guide





- Clinical Indications
- Patient Tolerance/ comfort/pain avoidance
- Hx. w/ documented therapy effectiveness
- Observation of effectiveness w/trial

ACT Therapy

PocketPEP vPEP iPEP

Combined Indications ACT & VET

PocketPep w/OxyJET vPEP w/OxyJET (Dual Therapy)

Volume Expansion

OxyPAP PAP Therapy OxyTrainer

Therapy Contraindications Present?

Re-evaluate **Indications: Contact Provider**

Administer Therapy 4 times Daily & PRN as Tolerated

Patients w/ Increased Symptoms: Consider Escalation to Dual Therapy **OPEP/PAP**

Re-Evaluate Patient every 24-hours for Therapy Efficacy

Assess Outcomes/Goals Achieved?

- Resolution/Improvement in Chest CXR/CT/MRI
- Decreased RR and WOB
- Improved Lung sounds via Auscultation
- Increased SPO2 / Improved alveolar oxygenation
- Improvement in VC and PEFs
- Optimal hydration w/sputum production



Consider: decrease frequency or discontinuing therapy



Re-evaluate indications/ **Contact Provider**

Note: Patients w/ chronic pulmonary disease who maintain secretion clearance therapy in their home environment

should remain on treatment no less than their home frequency

©2020. All tradenames property of D•R Burton Healthcare. 728rev01